Recent Updates
Recently added Catalysts

Malaria Vaccine 257049

Phase 3

Malaria | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Nov 25, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment18,543
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02207816An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in AfricaPHASE3 COMPLETED 3,084Sep 18, 2014Jan 31, 2017Nov 25, 20193 Burkina Faso, Kenya +1
NCT00866619Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in AfricaPHASE3 COMPLETED 15,459Mar 27, 2009Jan 31, 2014Oct 9, 201910 Burkina Faso, Gabon +5
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of Severe Malaria Meeting Case Definition 1
From Year 0 to Year 3 (Starting January 2014 and ending December 2016)

Case definition 1 for severe malaria was defined as an episode of malaria with positive Plasmodium falciparum asexual parasitemia (within -1 to +3 days of admission) and with one or more marker of disease severity: Prostration, respiratory distress, Blantyre score equal to or less than (≤) 2, seizures 2 or more, hypoglycemia below (\<) 2.2 millimoles per liter (mmol/L), acidosis BE ≤ -10.0 mmol/L, lactate ≥ 5.0 mmol/L or anemia \< 5.0 grams per deciliter (g/dL). The incidence of severe malaria for case definition 1 is expressed as a person year rate for each group (n/T), representing the number of events (n) reported over the risk period, which was counted in days and expressed as person years at risk (T).

Incidence of Severe Malaria Meeting Case Definition 2.
From Year 0 to Year 3 (Starting January 2014 and ending December 2016)

Case definition 2 for severe malaria was defined as an episode of malaria with positive Plasmodium falciparum asexual parasitemia (within -1 to +3 days of admission) and with one or more marker of disease severity: Prostration, respiratory distress, Blantyre score equal to or less than (≤) 2, seizures 2 or more, hypoglycemia below (\<) 2.2 millimoles per liter (mmol/L), acidosis BE ≤ -10.0 mmol/L, lactate ≥ 5.0 mmol/L or anemia \< 5.0 grams per deciliter (g/dL) or SAE report including preferred terms (Malaria, Plasmodium falciparum infection or Cerebral malaria) within -1 to +3 days of admission. The incidence of severe malaria for case definition 2 is expressed as a person year rate for each group (n/T), representing the number of events (n) reported over the risk period, which was counted in days and expressed as person years at risk (T).

Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)
From Month 2.5 to Month 14

A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia was greater than (\>) 5000 parasites per microliter (µL) accompanied by the presence of fever \[axillary temperature greater than or equal to (≥) 37.5°C\] at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 5-17 months age category.

Rate of First or Only Clinical Episode of P. Falciparum Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)
From Month 2.5 to Month 14

A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia \> 5000 parasites/µL was accompanied by the presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is, person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 6-12 weeks (6-12W) age category.

Secondary Endpoints
Incidence of Clinical Malaria Meeting Case Definition
From Year 0 to Year 3 (Starting January 2014 and ending December 2016)
Number of Subjects With Malaria Hospitalization Meeting Case Definition 1.
From Year 0 to Year 3 (Starting January 2014 and ending December 2016)
Number of Subjects With Malaria Hospitalization Meeting Case Definition 2.
From Year 0 to Year 3 (Starting January 2014 and ending December 2016)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
GSK257049 GroupEXPERIMENTALMale or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
GSK257049 Comparator GroupACTIVE_COMPARATORMale or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
VeroRab/Menjugate Comparator GroupACTIVE_COMPARATORMale or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
GSK257049 [5-17M] GroupEXPERIMENTALMale or female children between and including 5 to 17 months of age \[5-17M\], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
GSK257049 [6-12W] GroupEXPERIMENTALMale or female children between and including 6 to 12 weeks of age \[6-12W\], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
VeroRab Comparator [5-17M] GroupACTIVE_COMPARATORMale or female children between and including 5 to 17 months of age \[5-17M\], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
Menjugate Comparator [6-12W] GroupEXPERIMENTALMale or female children between and including 6 to 12 weeks of age \[6-12W\], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
Interventions
NameTypeDescription
Blood samplingPROCEDUREAnnual blood sampling (Year 1, Year 2 and Year 3) during the present study.
Malaria Vaccine 257049 (MALARIA-055 PRI)BIOLOGICALAdministered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)BIOLOGICALAdministered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
Cell-culture rabies vaccine (MALARIA-055 PRI)BIOLOGICALAdministered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
TritanrixHepB/Hib (MALARIA-055 PRI)BIOLOGICALAdministered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)BIOLOGICALAdministered orally, during the MALARIA-055 study (NCT00866619).
Malaria Vaccine 257049BIOLOGICALadministered intramuscularly into the left deltoid.
Meningococcal C Conjugate VaccineBIOLOGICALadministered intramuscularly into the left deltoid.
Cell-culture rabies vaccineBIOLOGICALadministered intramuscularly into the left deltoid.
TritanrixHepB/HibBIOLOGICALadministered intramuscularly into the left deltoid.
Polio Sabin Oral Polio Vaccine (GSK)BIOLOGICALadministered orally.
Unlock Study Design Details
Eligibility Criteria
Age Range42 Months — 9 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: * Subjects' parent(s)/ Legally Acceptable Representative (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Subjects who were enrolled and who received at least one vaccine dose in the primary study MALARIA-055 PRI NCT008...

Countries:Burkina FasoKenyaTanzaniaGabonGhanaMalawiMozambique
Unlock Eligibility Criteria
Competitive Landscape -Malaria 8 trials